Vanguard Group
RGNX icon

Vanguard Group’s Regenxbio RGNX Stock Holding History

Vanguard Group’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$48.6M Buy
3,374,140
+36,042
+1% +$449K ﹤0.01% 2176
2025
Q3 		$32.2M Sell
3,338,098
-83,094
-2% -$735K ﹤0.01% 2387
2025
Q2 		$28.1M Sell
3,421,192
-51,796
-1% -$434K ﹤0.01% 2394
2025
Q1 		$24.8M Buy
3,472,988
+487,036
+16% +$3.62M ﹤0.01% 2411
2024
Q4 		$23.1M Sell
2,985,952
-1,383,039
-32% -$13M ﹤0.01% 2521
2024
Q3 		$45.8M Sell
4,368,991
-744,791
-15% -$9.08M ﹤0.01% 2219
2024
Q2 		$59.8M Buy
5,113,782
+236,901
+5% +$3.69M ﹤0.01% 2074
2024
Q1 		$103M Buy
4,876,881
+436,043
+10% +$7.76M ﹤0.01% 1850
2023
Q4 		$79.7M Buy
4,440,838
+64,265
+1% +$1.13M ﹤0.01% 1973
2023
Q3 		$72M Buy
4,376,573
+36,531
+0.8% +$662K ﹤0.01% 1967
2023
Q2 		$86.8M Buy
4,340,042
+23,021
+0.5% +$444K ﹤0.01% 1929
2023
Q1 		$81.6M Buy
4,317,021
+44,527
+1% +$985K ﹤0.01% 1919
2022
Q4 		$96.9M Buy
4,272,494
+4,952
+0.1% +$112K ﹤0.01% 1823
2022
Q3 		$113M Buy
4,267,542
+15,219
+0.4% +$452K ﹤0.01% 1720
2022
Q2 		$105M Buy
4,252,323
+181,861
+4% +$4.54M ﹤0.01% 1793
2022
Q1 		$135M Buy
4,070,462
+16,496
+0.4% +$458K ﹤0.01% 1772
2021
Q4 		$133M Buy
4,053,966
+44,784
+1% +$1.52M ﹤0.01% 1828
2021
Q3 		$168M Buy
4,009,182
+65,423
+2% +$2.35M ﹤0.01% 1702
2021
Q2 		$153M Buy
3,943,759
+7,527
+0.2% +$269K ﹤0.01% 1771
2021
Q1 		$134M Buy
3,936,232
+600,934
+18% +$25.6M ﹤0.01% 1795
2020
Q4 		$151M Buy
3,335,298
+88,200
+3% +$3.08M ﹤0.01% 1621
2020
Q3 		$89.4M Sell
3,247,098
-203,269
-6% -$6.63M ﹤0.01% 1742
2020
Q2 		$127M Sell
3,450,367
-94,538
-3% -$3.52M ﹤0.01% 1553
2020
Q1 		$115M Buy
3,544,905
+123,805
+4% +$5.16M ﹤0.01% 1449
2019
Q4 		$140M Buy
3,421,100
+229,397
+7% +$9.06M ﹤0.01% 1585
2019
Q3 		$114M Sell
3,191,703
-258,171
-7% -$10.5M ﹤0.01% 1653
2019
Q2 		$177M Buy
3,449,874
+44,452
+1% +$2.22M 0.01% 1432
2019
Q1 		$195M Buy
3,405,422
+17,318
+0.5% +$858K 0.01% 1358
2018
Q4 		$142M Buy
3,388,104
+582,135
+21% +$34.2M 0.01% 1461
2018
Q3 		$212M Buy
2,805,969
+947,671
+51% +$68.3M 0.01% 1343
2018
Q2 		$133M Buy
1,858,298
+573,718
+45% +$27.4M 0.01% 1629
2018
Q1 		$38.3M Buy
1,284,580
+61,860
+5% +$1.8M ﹤0.01% 2204
2017
Q4 		$40.7M Buy
1,222,720
+9,922
+0.8% +$299K ﹤0.01% 2167
2017
Q3 		$40M Buy
1,212,798
+130,337
+12% +$2.93M ﹤0.01% 2155
2017
Q2 		$21.4M Buy
1,082,461
+100,944
+10% +$1.95M ﹤0.01% 2420
2017
Q1 		$18.9M Buy
981,517
+184,700
+23% +$3.56M ﹤0.01% 2462
2016
Q4 		$14.8M Buy
796,817
+30,502
+4% +$583K ﹤0.01% 2559
2016
Q3 		$10.7M Buy
766,315
+196,380
+34% +$2.17M ﹤0.01% 2654
2016
Q2 		$4.56M Buy
569,935
+306,596
+116% +$3.4M ﹤0.01% 3034
2016
Q1 		$2.84M Buy
263,339
+60,017
+30% +$768K ﹤0.01% 3233
2015
Q4 		$3.38M Buy
203,322
+173,356
+579% +$3.44M ﹤0.01% 3178
2015
Q3 		$660K Buy
+29,966
New +$765K ﹤0.01% 3763

Other funds holding RGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group's RGNX Position: Q4 2025 in Review

Vanguard Group increased its Regenxbio (RGNX) stake by 1.1% in Q4 2025, buying an estimated $449K and bringing the position to 3,374,140 shares worth $48.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2176.

Vanguard Group first reported a position in RGNX in Q3 2015 and has held it in 42 quarters since. The position peaked at $212M in Q3 2018. 174 funds tracked by Wall St. Rank hold RGNX as of Q4 2025.

  • Vanguard Group held 3,374,140 shares of Regenxbio worth $48.6M as of Q4 2025.
  • Vanguard Group bought 36,042 Regenxbio shares in Q4 2025, an estimated $449K.
  • Regenxbio made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2176 holding.
  • Vanguard Group first reported a position in Regenxbio in Q3 2015 and has held it in 42 quarters since.
  • Vanguard Group's Regenxbio position peaked at $212M in Q3 2018.
  • 174 funds tracked by Wall St. Rank held Regenxbio as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.